Terms: = Kidney tumors AND FOXP3, AIID, DIETER, IPEX, JM2, PIDX, XPID
113 results:
1. Pyroptosis-Related Subtypes Predict the Response of Clear Cell Renal Cell Carcinoma to Targeted Therapy.
Ma J; Kang Z; Yang G; Wang X; Si M; Wang Y; Li G; Bai S; Zeng F; Li M; Wang Z; Wang L; Xu W
Front Biosci (Landmark Ed); 2023 Dec; 28(12):334. PubMed ID: 38179741
[TBL] [Abstract] [Full Text] [Related]
2. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
[TBL] [Abstract] [Full Text] [Related]
3. Radiomics Model for Predicting foxp3 Expression Level and Survival in Clear Cell Renal Carcinoma.
Wang J; Huang Z; Zhou J
Acad Radiol; 2024 Apr; 31(4):1447-1459. PubMed ID: 37940428
[TBL] [Abstract] [Full Text] [Related]
4. TIGIT may Serve as a Potential Target for the Immunotherapy of Renal Cell Carcinoma.
Hong X; Yu C; Bi J; Liu Q; Wang Q
Adv Biol (Weinh); 2024 Jan; 8(1):e2300050. PubMed ID: 37690824
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and predictive significance of GITR in metastatic renal cell carcinoma.
Balçık OY; Akın D; Ceylan GS; Demİr B; Aytaç A; Çulhacı N; Oktay E
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7781-7792. PubMed ID: 37667956
[TBL] [Abstract] [Full Text] [Related]
6. Identification of immunogenic cell death-related signature on prognosis and immunotherapy in kidney renal clear cell carcinoma.
Jiang S; Dong Y; Wang J; Zhang X; Liu W; Wei Y; Zhou H; Shen L; Yang J; Zhu Q
Front Immunol; 2023; 14():1207061. PubMed ID: 37662929
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a novel combination treatment strategy in clear cell renal cell carcinoma stem cells with shikonin and ipilimumab.
Lyu C; Stadlbauer B; Wang L; Buchner A; Pohla H
Front Immunol; 2023; 14():1186388. PubMed ID: 37622107
[TBL] [Abstract] [Full Text] [Related]
8. Investigating the Role of
Xu S; Hu X; Chong Y; Zhu G
Int J Mol Sci; 2023 Aug; 24(15):. PubMed ID: 37569676
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features.
Takamatsu D; Kiyozawa D; Kohashi K; Kinoshita F; Toda Y; Ishihara S; Eto M; Oda Y
Pathol Res Pract; 2023 Apr; 244():154423. PubMed ID: 36989848
[TBL] [Abstract] [Full Text] [Related]
10. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
Zhou S; Lu Y; Chen Y; Gan W
Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
[TBL] [Abstract] [Full Text] [Related]
11. Depletion of Mannose Receptor-Positive Tumor-associated Macrophages via a Peptide-targeted Star-shaped Polyglutamate Inhibits Breast Cancer Progression in Mice.
Lepland A; Malfanti A; Haljasorg U; Asciutto EK; Pickholz M; Bringas M; Đorđević S; Salumäe L; Peterson P; Teesalu T; Vicent MJ; Scodeller P
Cancer Res Commun; 2022 Jun; 2(6):533-551. PubMed ID: 36923553
[TBL] [Abstract] [Full Text] [Related]
12. BAP1 and PTEN mutations shape the immunological landscape of clear cell renal cell carcinoma and reveal the intertumoral heterogeneity of T cell suppression: a proof-of-concept study.
Friedhoff J; Schneider F; Jurcic C; Endris V; Kirchner M; Sun A; Bolnavu I; Pohl L; Teroerde M; Kippenberger M; Schwab C; Kaczorowski A; Zschäbitz S; Jäger D; Hohenfellner M; Stenzinger A; Duensing A; Duensing S
Cancer Immunol Immunother; 2023 Jun; 72(6):1603-1618. PubMed ID: 36562826
[TBL] [Abstract] [Full Text] [Related]
13. Identification and experimental validation of a tumor-infiltrating lymphocytes-related long noncoding RNA signature for prognosis of clear cell renal cell carcinoma.
Deng Y; Guo K; Tang Z; Feng Y; Cai S; Ye J; Xi Y; Li J; Liu R; Cai C; Tan Z; Zhang Y; Han Z; Zeng G; Zhong W
Front Immunol; 2022; 13():1046790. PubMed ID: 36505457
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma.
Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996
[TBL] [Abstract] [Full Text] [Related]
15. Unique characteristics of tertiary lymphoid structures in kidney clear cell carcinoma: prognostic outcome and comparison with bladder cancer.
Masuda T; Tanaka N; Takamatsu K; Hakozaki K; Takahashi R; Anno T; Kufukihara R; Shojo K; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Aimono E; Nishihara H; Mizuno R; Oya M
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35314433
[TBL] [Abstract] [Full Text] [Related]
16. STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.
Yin M; Hu J; Yuan Z; Luo G; Yao J; Wang R; Liu D; Cao B; Wu W; Hu Z
Cell Cycle; 2022 Apr; 21(8):767-779. PubMed ID: 35130108
[TBL] [Abstract] [Full Text] [Related]
17. Bladder carcinomas in patients with neurogenic bladder and urinary schistosomiasis: are they the same tumors?
Cancrini F; Michel F; Cussenot O; Alshehhi H; Comperat E; Phé V
World J Urol; 2022 Aug; 40(8):1949-1959. PubMed ID: 35091808
[TBL] [Abstract] [Full Text] [Related]
18. Comprehensive Multi-Omics Identification of Interferon-γ Response Characteristics Reveals That RBCK1 Regulates the Immunosuppressive Microenvironment of Renal Cell Carcinoma.
Xu W; Tao J; Zhu W; Liu W; Anwaier A; Tian X; Su J; Shi G; Huang H; Wei G; Li C; Qu Y; Zhang H; Ye D
Front Immunol; 2021; 12():734646. PubMed ID: 34795663
[TBL] [Abstract] [Full Text] [Related]
19. Multiplexed single-cell pathology reveals the association of CD8 T-cell heterogeneity with prognostic outcomes in renal cell carcinoma.
Murakami T; Tanaka N; Takamatsu K; Hakozaki K; Fukumoto K; Masuda T; Mikami S; Shinojima T; Kakimi K; Tsunoda T; Sawada K; Imamura T; Mizuno R; Oya M
Cancer Immunol Immunother; 2021 Oct; 70(10):3001-3013. PubMed ID: 34259900
[TBL] [Abstract] [Full Text] [Related]
20. Non-invasive Detection of Immunotherapy-Induced Adverse Events.
Ferreira CA; Heidari P; Ataeinia B; Sinevici N; Sise ME; Colvin RB; Wehrenberg-Klee E; Mahmood U
Clin Cancer Res; 2021 Oct; 27(19):5353-5364. PubMed ID: 34253581
[TBL] [Abstract] [Full Text] [Related]
[Next]
